{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-24-000070","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2024-06-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.925959+00:00","generated_at":"2026-06-01T02:22:24.371760+00:00","sec_items":["1.01","7.01","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ANI Pharma to acquire Alimera Sciences for $5.50/share + CVR, funded by $280M debt","bullets":["Deal consideration: $5.50 cash plus one CVR per Alimera share; adds ~$105M in branded revenue to ANI's rare disease segment.","CVR pays up to $0.25 per milestone: $0.25 if 2026 net revenue > $140M, $0.25 if 2027 net revenue > $160M.","Financing: $280M committed debt from JPMorgan and Blackstone; deal expected to close by Dec 21, 2024.","Accretion: high single to low double digit adj. non-GAAP EPS accretion in 2025; $35-38M adj. EBITDA incl. $10M cost synergies.","Caligan Partners (~32.1% holder) agreed to vote in favor; termination fee $10.4M under certain conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-24-000070","json":"https://secwatch.observer/filing/0001023024-24-000070.json","markdown":"https://secwatch.observer/filing/0001023024-24-000070.md","text":"https://secwatch.observer/filing/0001023024-24-000070.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000070/0001023024-24-000070-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000070/ani-20240621.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T02:22:24.371760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}